Understanding how proteins change to create new drugs
Molecular Mechanisms Remodeling Dynamic Landscapes in Multidomain Enzymatic Factories
['FUNDING_OTHER'] · JOHNS HOPKINS UNIVERSITY · NIH-11011175
This study is looking at how certain important proteins work together and change shape, which could help scientists create better medicines, like antibiotics and cancer treatments, for people who need them.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11011175 on ClinicalTrials.gov |
What this research studies
This research investigates the dynamic behavior of multidomain proteins, specifically focusing on nonribosomal peptide synthetases (NRPSs) that are crucial for synthesizing complex natural products with therapeutic benefits. By using advanced techniques like nuclear magnetic resonance (NMR) spectroscopy and computational modeling, the team aims to uncover how different protein domains interact and change, which can lead to the development of improved pharmaceuticals, including antibiotics and anti-cancer agents. The goal is to create a deeper understanding of protein dynamics to facilitate the engineering of these proteins for better drug design.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with conditions that could benefit from new antibiotic or anti-cancer therapies.
Not a fit: Patients with conditions unrelated to antibiotic resistance or cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective antibiotics and anti-cancer drugs.
How similar studies have performed: Other research has shown promise in engineering proteins for drug development, indicating that this approach could yield significant advancements.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FRUEH, DOMINIQUE PASCAL — JOHNS HOPKINS UNIVERSITY
- Study coordinator: FRUEH, DOMINIQUE PASCAL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug